Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:MET

Metlife (MET)

87.86
+0.20 (0.23%)
as of Jun 16, 2026, 4:51:53 pm Market Open.
36 watching
0
Investor Insights
star iconJun 16, 2026, 12:00 am

This summary was created by AI, based on 1 opinions in the last 12 months.

MetLife (MET-N) has demonstrated strong performance recently, as indicated by its recent achievement of a 52-week high. The company is viewed favorably by experts for its strategic investments in solid and conservative sectors, which add to its appeal as a defensive stock. This positive sentiment suggests that MetLife is successfully navigating the financial landscape, with a focus on stability and sustainability. Investors seem to appreciate its prudent approach to asset management and its ability to deliver reliable returns in uncertain market conditions. Overall, MetLife stands out as a robust option for investors seeking defensive plays in their portfolios.

consensus icon
Consensus
Positive
valuation icon
Valuation
Fair Value
review icon
Similar
PRU

Most recent Opinions go here

Be up to date, don't miss your chance.

BUY

Just made a 52-week high. Solid, conservative and defensive, invested in the right things.

HOLD

Higher rates are actually good for insurance companies. Yield is about 2.9%, growing at single digits and he prefers double-digit growth. The whole industry has a tailwind, and you can see it if you look at the KIE ETF.

DON'T BUY

Does not own shares. Financial services and insurance. Valuation is low and could be good time for investors. Does not own shares. Fundamentally a 6/10. Could be volatile. Better options out there for investors. 

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Sep 27/22, Up 7.4%)Stockchase Research Editor: Michael O’Reilly

Our PAST TOP PICK with MET has triggered its stop at $65.  To remain disciplined, we recommend covering the position at this time.

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Sep 27/22, Up 27.2%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MET has achieved its target at $77. To remain disciplined, we recommend covering half the position and trailing up the stop loss (from $62) to $67. If triggered, this would result in a net investment gain of 18%.
HOLD
Switch from Canadian insurers to MET? Hit a new high today. Likes it. Financials are at a historical discount. Likes banks, insurers and diversified financials. He wouldn't switch, as some Canadian valuations are quite cheap. Nice dividend of 2.6%.
HOLD
Model price of $87.26, 18% upside. Market really liked its write down on balance sheet or spinoff. Likes it here. Turned itself around. Will probably go to $80, and he'll evaluate it there.
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Sep 27/22, Up 22.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MET is progressing well. To remain disciplined, we now recommend trailing up the stop (from $52.50) to $62.00.
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly This world leader in insurance and benefits is a TOP PICK. The company just announced a deal along with PRU to assume the $16 billion pension obligation of IBM -- right up its alley. We like the value here as the company is trading under book value, just beat analyst earnings expectations, and is projected to trade 7x earnings. It has managed to increase cash reserves, while aggressively retiring debt and buying back shares. Its dividend is backed by a payout ratio under 50% of cash flow. We recommend placing a stop loss at $52.50, looking to achieve $77 -- upside potential of 25%. Yield 3.2% (Analysts’ price target is $77.25)
BUY
The insurers have been in fire, like MetLife. He believes rates will go higher, so definitely stick with them.
DON'T BUY
It's fine, but he does not likes financials (or energy). He just likes MET's yield and that's it.
COMMENT

AIG-N vs. MET-N. AIG-N has been recapitalizing since the disaster of the financial crisis. MET-N did not suffer these issues. The life business is in pretty decent shape but he prefers Canadian lifecos. (Analysts’ price target is $55.57)

BUY
It’s pretty cheap, trading at 8.1 times. Their earnings in July were double year over year and beat expectations. They are growing globally and it’s a safe name with a low valuation. Couldn’t go wrong with this choice in the long term.
WAIT
MET vs. BAC. Dynamics of the two are different, so hard to compare. FMV potential of both is huge. But the market won't go, because interest rates are falling. Aren't any drivers to escalate earnings. Very cheap, but who knows when they're going to pop? (Analysts’ price target is $53.19)
DON'T BUY
The balance sheet is impaired and there should be write-offs, which he hasn't seen. He sees 32% upside with a $64 model price, but he'd be happy seeing this at $53.80. He would recommend this stock above this price. He has recommended MET before, but MET just can't get going. The balance sheet is ugly. Also, if interest rates fall to zero, all insurance companies will get hit.
Showing 1 to 15 of 112 entries

Metlife (MET) Frequently Asked Questions

What is Metlife stock symbol?

Metlife is a American stock, trading under the symbol MET (previously MET-N on Stockchase) on the New York Stock Exchange (MET). It is usually referred to as NYSE:MET or MET

Is Metlife a buy or a sell?

In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on MET (previously MET-N on Stockchase). 1 analyst recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is DON'T BUY. Read the latest stock experts' ratings for Metlife.

Is Metlife a good investment or a top pick?

Metlife was recommended as a Top Pick by Brian Acker, CA on 2019-06-14. Read the latest stock experts ratings for Metlife.

Why is Metlife stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Metlife.

Is Metlife worth watching?

Metlife is followed by 36 investors on Stockchase and is a trending stock that is worth watching.

What is Metlife stock price?

On 2026-06-16, Metlife (MET) stock closed at a price of $87.86.